NO912511D0 - Fremgangsmaate for forhindring eller begrensning av reperfusjonsskade - Google Patents

Fremgangsmaate for forhindring eller begrensning av reperfusjonsskade

Info

Publication number
NO912511D0
NO912511D0 NO1991912511A NO912511A NO912511D0 NO 912511 D0 NO912511 D0 NO 912511D0 NO 1991912511 A NO1991912511 A NO 1991912511A NO 912511 A NO912511 A NO 912511A NO 912511 D0 NO912511 D0 NO 912511D0
Authority
NO
Norway
Prior art keywords
refusion
prevention
restriction
damage
procedure
Prior art date
Application number
NO1991912511A
Other languages
English (en)
Other versions
NO912511L (no
NO304519B1 (no
Inventor
Herman Van Belle
Willy Joannes Carolu Laerhoven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO912511D0 publication Critical patent/NO912511D0/no
Publication of NO912511L publication Critical patent/NO912511L/no
Publication of NO304519B1 publication Critical patent/NO304519B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Protection Of Pipes Against Damage, Friction, And Corrosion (AREA)
  • Dicing (AREA)
  • Branch Pipes, Bends, And The Like (AREA)
  • Golf Clubs (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • External Artificial Organs (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
NO912511A 1989-11-22 1991-06-26 Fremstilling av (1)-(-)-2-(aminokarbonyl)-N-(4-amino-2,6-diklorfenyl)-4-[5,5-bis(4-fluorfenyl)pentyl]-1-piperazinacetamid NO304519B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44014289A 1989-11-22 1989-11-22
PCT/EP1990/001985 WO1991007967A2 (en) 1989-11-22 1990-11-19 Method of preventing or limiting reperfusion damage
SG118494A SG118494G (en) 1989-11-22 1994-08-20 Method of preventing or limiting reperfusion damage

Publications (3)

Publication Number Publication Date
NO912511D0 true NO912511D0 (no) 1991-06-26
NO912511L NO912511L (no) 1991-08-26
NO304519B1 NO304519B1 (no) 1999-01-04

Family

ID=26664237

Family Applications (2)

Application Number Title Priority Date Filing Date
NO912511A NO304519B1 (no) 1989-11-22 1991-06-26 Fremstilling av (1)-(-)-2-(aminokarbonyl)-N-(4-amino-2,6-diklorfenyl)-4-[5,5-bis(4-fluorfenyl)pentyl]-1-piperazinacetamid
NO19982078A NO311701B1 (no) 1989-11-22 1998-05-07 Fremgangsmåte for beskyttelse av et donorhjerte for transplantering samt anvendelse av en N-aryl-piperazinalkanamidforbindelse for dette formål

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19982078A NO311701B1 (no) 1989-11-22 1998-05-07 Fremgangsmåte for beskyttelse av et donorhjerte for transplantering samt anvendelse av en N-aryl-piperazinalkanamidforbindelse for dette formål

Country Status (22)

Country Link
EP (2) EP0577171B1 (no)
JP (1) JP2574585B2 (no)
KR (1) KR0165686B1 (no)
AT (2) ATE102831T1 (no)
AU (1) AU632888B2 (no)
CA (1) CA2044143C (no)
CY (1) CY1869A (no)
DE (2) DE69007471T2 (no)
DK (2) DK0577171T3 (no)
ES (2) ES2053208T3 (no)
FI (1) FI109694B (no)
HK (1) HK115095A (no)
HU (1) HU215847B (no)
IE (1) IE65121B1 (no)
IL (1) IL96390A (no)
NO (2) NO304519B1 (no)
NZ (1) NZ236168A (no)
PT (2) PT95959B (no)
RU (1) RU2093156C1 (no)
SG (1) SG118494G (no)
WO (1) WO1991007967A2 (no)
ZA (1) ZA909345B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9202266D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
BR0209678A (pt) 2001-05-18 2004-09-14 Astrazeneca Ab Composto, processo para preparar e uso do mesmo, composição farmacêutica, e, métodos para o tratamento da dor e de distúrbios gastrintestinais funcionais
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
CA2575975A1 (en) * 2003-11-12 2005-05-26 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
DK1781631T3 (da) 2004-08-02 2012-05-14 Astrazeneca Ab Diarylmethylpiperazinderivater, præparater dermed og anvendelser deraf
FR2946340B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
KR101900124B1 (ko) 2014-06-25 2018-09-18 전남대학교산학협력단 전복 박리용 조성물
KR101644299B1 (ko) 2014-07-22 2016-08-02 주식회사 엔바이로젠 오미자 및 삼채 추출물을 유효성분으로 포함하는 전복 박리용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
DE69033926T2 (de) 2002-10-24
ATE102831T1 (de) 1994-04-15
SG118494G (en) 1994-11-25
FI913433A0 (fi) 1991-07-16
HK115095A (en) 1995-07-21
RU2093156C1 (ru) 1997-10-20
EP0455789A1 (en) 1991-11-13
PT102145A (pt) 1999-10-29
IE904209A1 (en) 1991-05-22
AU632888B2 (en) 1993-01-14
CA2044143C (en) 2002-11-19
JP2574585B2 (ja) 1997-01-22
AU6876391A (en) 1991-06-26
PT95959A (pt) 1991-09-13
KR920700644A (ko) 1992-08-10
ZA909345B (en) 1992-08-26
NZ236168A (en) 1993-05-26
CA2044143A1 (en) 1991-05-23
EP0577171A3 (en) 1994-06-29
PT102145B (pt) 2002-06-28
PT95959B (pt) 1998-08-31
EP0455789B1 (en) 1994-03-16
IL96390A (en) 1995-06-29
DE69007471T2 (de) 1994-06-23
DK0577171T3 (da) 2002-06-03
NO912511L (no) 1991-08-26
WO1991007967A3 (en) 1991-07-11
CY1869A (en) 1996-04-05
NO311701B1 (no) 2002-01-14
DE69007471D1 (de) 1994-04-21
DE69033926D1 (de) 2002-04-11
IE65121B1 (en) 1995-10-04
WO1991007967A2 (en) 1991-06-13
HUT58709A (en) 1992-03-30
HU215847B (hu) 1999-04-28
EP0577171A2 (en) 1994-01-05
NO982078L (no) 1991-08-26
FI109694B (fi) 2002-09-30
IL96390A0 (en) 1991-08-16
DK0455789T3 (da) 1994-04-05
ES2053208T3 (es) 1994-07-16
NO304519B1 (no) 1999-01-04
ES2173883T3 (es) 2002-11-01
HU9102436D0 (en) 1991-12-30
ATE213943T1 (de) 2002-03-15
EP0577171B1 (en) 2002-03-06
NO982078D0 (no) 1998-05-07
KR0165686B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
NO912511L (no) Fremgangsmaate for forhindring eller begrensning av reperfusjonsskade
FI850078L (fi) N-(4-piperidinyl)-bicykliska -kondenserade 2-imidazolaminderivat.
PT96145A (pt) Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem
FI950309A (fi) Proliiniamidijohdannaisia
NO932745D0 (no) Triazolyltiometyltiocefalosporin-hydroklorid, dets krystalliske hydrat samt fremgangsmaate for fremstilling
NO172690C (no) Analogifremgangsmaate for fremstilling av 5,6-dihydro-2-(substituert fenyl)-1,2,4-triazin-3,5(2h,4h)-dioner
ES2052015T3 (es) Un metodo de preparacion de una composicion farmaceutica.
FI933719A0 (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
FI872930A0 (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
AU4239089A (en) New 1,4-dihydropyridinederivative, namely (-)-2-{(2- aminoethoxy) ethoxy)-4-(2,3-dichlorophenyl)-3- ethoxycarbonyl-50methoxycarbonyl-6-methyl}-1,4- dihydropyridine, process for preparing it and pharmaceutical compositions containing it